ČESKÁ UROLOGIE / CZECH UROLOGY – 2 / 2019

147 KAZUISTIKA Ces Urol 2019; 23(2): 140–148 11. Babjuk M, Soukup V. Intravezikální léčba povrchových nádorů močového měchýře. Urolog. praxi 2004; 3: 116–120. 12. Král M, Mucha Z, Študent V. Imunoterapie karcinomu močového měchýře. Onkologie 2013; 7(1): 30–34. 13. Moniruzzaman M, Islam S, Chandra S, Koli A, Hassan MJ. Tuberculosis and Deep Venous Thrombosis, a rare complication of a common disease: A case report. KYAMC Journal 2017; 6(1): 598–600. 14. Cobas Pas A, Garcia Tejedor JL, González Pineiro A, Fernández‑Villar A. Miliary tuberculosis due to BCG in an asymptomatic patient: initial onset or a condition not yet described? Tuberculosis miliar por BCG en un paciente asintomático: ¿afectación inicial o una entidad no descrita? Archivos de Bron‑ coneumología 2010; 46(7): 394–395. 15. Dammert P, Boujaoude Z, Rafferty W, Kass J. Fever of unknown origin and pancytopenia caused by culture‑proven delayed onset disseminated bacillus Calmette‑Guerin (BCG) infection after intravesical instillation. Case Reports 2013; 2013: bcr2013008949. 16. Manfredi R, Dentale N, Piergentili B, Pultrone C, Brunocilla E. Tubercular Disease Caused by Bacillus of Calmette‑Guérin as a Local Adjuvant Treatment of Relapsing Bladder Carcinoma. Cancer Biotherapy and Radiopharmaceuticals 2009; 24(5): 621–627. 17. Siatelis A, Houhoula DP, Papaparaskevas J, Delakas D, Tsakris A. Detection of Bacillus Galmette‑Guerin ( Mycobacterium bovis BCG) DNA in Urine and Blood Specimens after Intravesical Immunotherapy for Bladder Carcinoma. Journal of Clinical Microbiology 2011; 49(4): 1206–1208. 18. Sheth JS, Belperio JA, Fishbein MC, et al. Utility of Transbronchial vs. Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. Chest 2017; 151(2): 389–399. 19. Tomasetti S, Wells A U, Costabel U, et al. Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confi‑ dence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2016; 193(7): 745–752. 20. Sharp C, Mccabe M, Adamali H, Medford AR. Use of transbronchial cryobiopsy in the diagnosis of interstitial lung disease - a systematic review and cost analysis. An International Journal of Medicine 2017; 110(4): 207–214. 21. Delimpoura V, Samitas K, Vamvakaris I, Zervas E, Gaga M. Concurrent granulomatous hepatitis, pneu‑ monitis and sepsis as a complication of intravesical BCG immunotherapy. Case Reports 2013; bcr2013200624. 22. Watts MR, Taylor PC, Sintchenko V, et al. Implications of Isoniazid Resistance in Mycobacterium bovis Bacillus Calmette‑Guerin used for Immunotherapy in Bladder Cancer. Clinical Infectious Diseases 2011; 52(1): 86–88. 23. Durek C, Rüsch‑Gerdes S, Jocham D, Böhle A. Sensitivity of BCG to Modern Antibiotics. European Urology 2000; 37(Suppl. 1): 21–25. 24. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR. Empiric Treatment of Community Acquired Pneumonia with Fluoroquinolones, and Delays in the Treatment of Tuberculosis. Clinical Infectious Diseases 2002; 34(12): 1607–1612. 25. Gonzalez OY, Musher DM, Brar I, et al. Spectrum of Bacille Calmette Guerin (BCG) Infection after Intravesical BCG Immunotherapy. Clinical Infectious Diseases 2003; 36(2): 140–148. 26. Fluorochinolony pro systémové a inhalační podání: riziko aneurysmatu aorty a aortální disekce [online]. Státní ústav pro kontrolu léčiv [cit. 17. 10. 2018]. Dostupné z: http://www.sukl.cz/leciva/informacni‑dopis‑fluorochinolony. 27. Fluorochinolonová antibiotika – omezení používání potvrzeno [online]. Státní ústav pro kontrolu léčiv [cit. 22. 11. 2018]. Dostupné z: http://www.sukl.cz/fluorochinolonova‑antibiotika‑omezeni‑pouzivani‑potvrzeno. 28. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG Intravesical Instillations: Recommen‑ dations for Side‑Effects Management. European Urology 2000; 37(suppl 1): 33–36.